Comparative Analysis of Simian Immunodeficiency Virus Gag-Specific Effector and Memory CD8+ T Cells Induced by Different Adenovirus Vectors
- Wendy G. Tana,*,
- Hyun-Tak Jina,*,
- Erin E. Westa,*,
- Pablo Penaloza-MacMasterc,
- Andreas Wielanda,
- Michael J. Zillioxa,*,
- M. Juliana McElrathe,
- Dan H. Barouchb,c,d and
- Rafi Ahmeda,b
- aEmory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA
- bCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery
- cCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
- dRagon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA
- eFred Hutchinson Cancer Research Institute, Seattle, Washington, USA
ABSTRACT
Adenovirus (Ad) vectors are widely used as experimental vaccines against several infectious diseases, but the magnitude, phenotype, and functionality of CD8+ T cell responses induced by different adenovirus serotypes have not been compared. To address this question, we have analyzed simian immunodeficiency virus Gag-specific CD8+ T cell responses in mice following vaccination with Ad5, Ad26, and Ad35. Our results show that although Ad5 is more immunogenic than Ad26 and Ad35, the phenotype, function, and recall potential of memory CD8+ T cells elicited by these vectors are substantially different. Ad26 and Ad35 vectors generated CD8+ T cells that display the phenotype and function of long-lived memory T cells, whereas Ad5 vector-elicited CD8+ T cells are of a more terminally differentiated phenotype. In addition, hepatic memory CD8+ T cells elicited by Ad26 and Ad35 mounted more robust recall proliferation following secondary challenge than those induced by Ad5. Furthermore, the boosting potential was higher following priming with alternative-serotype Ad vectors than with Ad5 vectors in heterologous prime-boost regimens. Anamnestic CD8+ T cell responses were further enhanced when the duration between priming and boosting was extended from 30 to 60 days. Our results demonstrate that heterologous prime-boost vaccine regimens with alternative-serotype Ad vectors elicited more functional memory CD8+ T cells than any of the regimens containing Ad5. In summary, these results suggest that alternative-serotype Ad vectors will prove useful as candidates for vaccine development against human immunodeficiency virus type 1 and other pathogens and also emphasize the importance of a longer rest period between prime and boost for generating optimal CD8+ T cell immunity.
FOOTNOTES
- Received 7 August 2012.
- Accepted 8 November 2012.
- Address correspondence to Rafi Ahmed, rahmed{at}emory.edu, or Dan H. Barouch, dbarouch{at}bidmc.harvard.edu.
-
↵* Present address: Wendy G. Tan, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA; Hyun-Tak-Jin, Research Institute, Genexine Co., Seongnam, Republic of Korea; Erin E. West, National Heart Lung and Blood Institute Immunology Center, National Institutes of Health, Bethesda, Maryland, USA; Michael J. Zilliox, Loyola University Center for Biomedical Informatics, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.
-
Published ahead of print 21 November 2012
- Copyright © 2013, American Society for Microbiology. All Rights Reserved.
The authors have paid a fee to allow immediate free access to this article.











